Keith Sullivan - Neuronetics CEO President
| STIM Stock | USD 3.49 0.03 0.85% |
CEO
Keith Sullivan is CEO President of Neuronetics
| Age | 66 |
| Phone | 610 640 4202 |
| Web | https://neurostar.com |
Keith Sullivan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Keith Sullivan against Neuronetics stock is an integral part of due diligence when investing in Neuronetics. Keith Sullivan insider activity provides valuable insight into whether Neuronetics is net buyers or sellers over its current business cycle. Note, Neuronetics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Neuronetics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Keith Sullivan over two months ago Disposition of 20292 shares by Keith Sullivan of Neuronetics at 3.3 subject to Rule 16b-3 | ||
Keith Sullivan over two months ago Disposition of 20750 shares by Keith Sullivan of Neuronetics at 3.23 subject to Rule 16b-3 | ||
Keith Sullivan over two months ago Disposition of 20851 shares by Keith Sullivan of Neuronetics at 3.23 subject to Rule 16b-3 | ||
Keith Sullivan over three months ago Sale by Keith Sullivan of 10013 shares of Neuronetics |
Neuronetics Management Efficiency
The company has return on total asset (ROA) of (0.1534) % which means that it has lost $0.1534 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6617) %, meaning that it created substantial loss on money invested by shareholders. Neuronetics' management efficiency ratios could be used to measure how well Neuronetics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | CEO Age | ||
| Evguenia MBA | Sera Prognostics | 50 | |
| Hamid Erfanian | Enzo Biochem | 54 | |
| Scott Hutton | BiodesixInc | 52 | |
| Victor Lawrick | Burning Rock BiotechLtd | 49 | |
| Timothy Damadian | Fonar | 60 | |
| John Aballi | Exagen Inc | 39 | |
Management Performance
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.15 |
Neuronetics Leadership Team
Elected by the shareholders, the Neuronetics' board of directors comprises two types of representatives: Neuronetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neuronetics. The board's role is to monitor Neuronetics' management team and ensure that shareholders' interests are well served. Neuronetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neuronetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony Pui, Vice President of International Commercial Development | ||
| Mark Klausner, Managing Partner | ||
| Stephen Campe, Independent Director | ||
| Rick Grubbs, Senior Accounts | ||
| Christopher Thatcher, President CEO, Director | ||
| Kara Thornton, VP Director | ||
| Glenn Muir, Independent Director | ||
| Keith Sullivan, CEO President | ||
| Rusty Page, Senior Quality | ||
| Steve MacKinnon, Vice President - Sales | ||
| Mark Bausinger, CFO | ||
| Stephen MS, CFO VP | ||
| Chris Thatcher, President CEO, Director | ||
| Lisa MetznerRosas, Senior Officer | ||
| Andrew Macan, Gen VP | ||
| Claire Sears, VP Marketing | ||
| Peter Donato, CFO, Vice President | ||
| Cory Anderson, Senior Clinical | ||
| Wilfred Jaeger, Independent Director | ||
| Daniel Guthrie, Chief Commercial Officer | ||
| Mark Demitrack, Chief Medical Officer | ||
| Stephen Furlong, CFO, Secretary | ||
| Ronald Hunt, Independent Director | ||
| Brian Farley, Independent Chairman of the Board | ||
| Yelena Tropsha, Vice President - Commercial Access | ||
| Gregory Harper, Vice President of Research and Development, Operations and Product Development | ||
| Sara Grubbs, Senior Officer | ||
| Cheryl Blanchard, Independent Director |
Neuronetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neuronetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 106.65 M | ||||
| Shares Outstanding | 29.97 M | ||||
| Shares Owned By Insiders | 6.31 % | ||||
| Shares Owned By Institutions | 65.18 % | ||||
| Number Of Shares Shorted | 57.69 K | ||||
| Price To Book | 3.76 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neuronetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neuronetics' short interest history, or implied volatility extrapolated from Neuronetics options trading.
Currently Active Assets on Macroaxis
When determining whether Neuronetics is a strong investment it is important to analyze Neuronetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuronetics' future performance. For an informed investment choice regarding Neuronetics Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Neuronetics Stock analysis
When running Neuronetics' price analysis, check to measure Neuronetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuronetics is operating at the current time. Most of Neuronetics' value examination focuses on studying past and present price action to predict the probability of Neuronetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuronetics' price. Additionally, you may evaluate how the addition of Neuronetics to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Neuronetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.